Physician

Lihong Wu, M.D.

According to 2025 Medicare claims, Lihong Wu, M.D. (NPI: 1932128410) practices hematology/oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 90808-1734.

Wu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 590 traditional Medicare patients, billed 244,238 HCPCS/CPT codes, and received $5,511,371 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,619 prescription claims across 199 beneficiaries totaling $5,749,191 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 38 claims. Open Payments data shows 2 records totaling $37. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,961,023 to $5,511,371. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,227,144 to $5,749,191. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	727	137,975	$1,961,023
2016	701	163,052	$1,791,725
2017	772	185,570	$1,959,642
2018	714	139,138	$1,985,257
2019	713	128,206	$2,400,595
2020	608	102,588	$2,165,747
2021	632	132,082	$3,029,636
2022	733	154,998	$2,937,411
2023	654	228,439	$4,099,108
2024	590	244,238	$5,511,371

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	155	1,220	$1,227,144
2016	146	1,130	$1,412,860
2017	147	1,253	$1,542,946
2018	136	1,126	$1,517,932
2019	112	888	$1,346,352
2020	124	968	$1,028,290
2021	124	990	$1,906,678
2022	144	1,044	$2,591,207
2023	165	1,277	$3,616,491
2024	199	1,619	$5,749,191

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	62	$40,291
2016	N/R	205	$184,806
2017	N/R	47	$14,504
2018	N/R	35	$5,635
2019	N/R	35	$3,450
2020	N/R	55	$4,040
2021	N/R	44	$3,717
2022	N/R	41	$1,481
2023	N/R	31	$5,542
2024	N/R	38	$1,307

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	238	538	$156
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	231	475	$105
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	119	397	$59
96375	Injection of additional new drug or substance into vein	81	711	$14
96372	Injection of drug or substance under skin or into muscle	145	531	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	53	1,590	$800,127
Verzenio	Abemaciclib	53	1,484	$778,518
Calquence	Acalabrutinib Maleate	47	1,410	$709,925
Ninlaro	Ixazomib Citrate	59	1,652	$703,197
Tagrisso	Osimertinib Mesylate	26	780	$403,890

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$968
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$37	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lihong Wu, M.D.?

Tedicare shows public-source Medicare data for Lihong Wu, M.D. (NPI 1932128410), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lihong Wu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lihong Wu, M.D.?

Lihong Wu, M.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Lihong Wu, M.D. have Open Payments data?

Lihong Wu, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.